Gamida Cell lands $40m for late-stage NiCord trial

Gamida Cell said today that it raised $40 million to support the ongoing Phase III trial of its NiCord cell graft and expand its in-house manufacturing capacity.

The private financing was led by new investor Shavit Capital. VMS Investment Group and Israel Biotech Fund joined existing investor Novartis in the round, as well as Clal Biotechnology Industries and Israel HealthCare ventures.

Get the full story at our sister site, Drug Delivery Business News.

The post Gamida Cell lands $40m for late-stage NiCord trial appeared first on MassDevice.

from MassDevice http://ift.tt/2tEYref